{
  "id": "5a7340962dc08e987e000017",
  "type": "yesno",
  "question": "Is Apremilast effective for Behcet\u2019s syndrome?",
  "ideal_answer": "Yes. Apremilast was proven to be effective for treatment of Behcet\u2019s syndrome.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/24882690",
    "http://www.ncbi.nlm.nih.gov/pubmed/24797159",
    "http://www.ncbi.nlm.nih.gov/pubmed/26487500",
    "http://www.ncbi.nlm.nih.gov/pubmed/26555450",
    "http://www.ncbi.nlm.nih.gov/pubmed/27163156",
    "http://www.ncbi.nlm.nih.gov/pubmed/25875256"
  ],
  "snippets": [
    {
      "text": "Apremilast is an immunomodulatory agent that works through phosphodiesterase 4 inhibition. A randomized controlled trial has shown that it is effective for the management of oral and genital ulcers and is generally well tolerated.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26555450",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AREAS COVERED: This review provides a digest of all current experience and evidence about pharmacological agents recently described as having a role in the treatment of BS, including interleukin (IL)-1 inhibitors, tocilizumab, rituximab, alemtuzumab, ustekinumab, interferon-alpha-2a, and apremilast.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27163156",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Apremilast was effective in treating oral ulcers, which are the cardinal manifestation of Beh\u00e7et's syndrome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Apremilast, an inhibitor of phosphodiesterase-4, was effective in a phase 2, double blind, placebo-controlled study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26487500",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apremilast (Otezla(\u00ae)), an oral small molecule inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4), is under development with Celgene Corporation for the treatment of psoriatic arthritis, psoriasis, ankylosing spondylitis, Beh\u00e7et's syndrome, atopic dermatitis, and rheumatoid arthritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24797159",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "There were two serious adverse events in patients receiving apremilast.<br><b>CONCLUSIONS</b>: Apremilast was effective in treating oral ulcers, which are the cardinal manifestation of Beh\u00e7et's syndrome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apremilast (Otezla(\u00ae)), an oral small molecule inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4), is under development with Celgene Corporation for the treatment of psoriatic arthritis, psoriasis, ankylosing spondylitis, Beh\u00e7et's syndrome, atopic dermatitis, and rheumatoid arthritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24797159",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS Apremilast was effective in treating oral ulcers, which are the cardinal manifestation of Beh\u00e7et's syndrome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Apremilast, an oral small molecule inhibitor of phosphodiesterase 4 (PDE4), is in development for chronic inflammatory disorders, and has shown efficacy in psoriasis, psoriatic arthropathies, and Beh\u00e7et's syndrome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24882690",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "oral ulcers the hallmark of beh\u00e7et s syndrome can be resistant to conventional treatment therefore alternative agents are needed apremilast is an oral phosphodiesterase 4 inhibitor that modulates several inflammatory pathways we conducted a phase 2 multicenter placebo controlled study in which 111 patients with beh\u00e7et s syndrome who had two or more oral ulcers were randomly assigned to receive 30 mg of apremilast twice daily or placebo for 12 weeks this regimen was followed by a 12 week extension phase in which the placebo group was switched to apremilast and a 28 day post treatment observational follow up phase the patients and clinicians were unaware of the study assignments throughout the trial the primary end point was the number of oral ulcers at week 12 secondary outcomes included pain from these ulcers measured on a 100 mm visual analogue scale with higher scores indicating worse pain the number of genital ulcers overall disease activity and quality of life the mean sd number of oral ulcers per patient at week 12 was significantly lower in the apremilast group than in the placebo group 0 5 1 0 vs 2 1 2 6 p 0 001 the mean decline in pain from oral ulcers from baseline to week 12 was greater with apremilast than with placebo 44 7 24 3 mm vs 16 0 32 5 mm p 0 001 nausea vomiting and diarrhea were more common in the apremilast group with 22 9 and 12 incidents respectively among 55 patients than in the placebo group with 10 1 and 2 incidents respectively among 56 patients findings that were similar to those in previous studies of apremilast there were two serious adverse events in patients receiving apremilast apremilast was effective in treating oral ulcers which are the cardinal manifestation of beh\u00e7et s syndrome this preliminary study was neither large enough nor long enough to assess long term efficacy the effect on other manifestations of beh\u00e7et s syndrome or the risk of uncommon serious adverse events funded by celgene clinicaltrials gov number nct00866359.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "current trends in the management of beh\u00e7et s syndrome will be reviewed in this article biologic agents have gained increasing importance over the years in the management of beh\u00e7et s syndrome long term results of observational studies have shown that anti tumor necrosis factor agents may be effective in beh\u00e7et s syndrome patients with refractory eye involvement case series reporting about use of anti tumor necrosis factor agents in vascular and gastrointestinal involvement have also shown good results caution is required for infectious complications with these agents apremilast is an immunomodulatory agent that works through phosphodiesterase 4 inhibition a randomized controlled trial has shown that it is effective for the management of oral and genital ulcers and is generally well tolerated the outcome of beh\u00e7et s syndrome with major organ involvement has improved with more effective management strategies especially with the use of biologic agents in severe cases controlled trials are needed to guide physicians in making treatment decisions.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26555450",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "https://meshb.nlm.nih.gov/record/ui?ui=D001528",
    "https://meshb.nlm.nih.gov/record/ui?ui=D016896",
    "http://www.disease-ontology.org/api/metadata/DOID:13241"
  ],
  "exact_answer": "Yes"
}